Compare Eli Lilly And Co (LLY) vs PulteGroup, Inc. (PHM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs PulteGroup, Inc. — how do they compare? Eli Lilly And Co trades at $1,177.57 (market cap $1.04T), while PulteGroup, Inc. trades at $112.04 (market cap $21.63B). The key difference: Eli Lilly And Co is far larger — about 48.1× PulteGroup, Inc.'s market cap, and PulteGroup, Inc. pays the higher dividend (0.92%). Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and PulteGroup, Inc. for 91 Days on average.
| LLY | PHM | |
|---|---|---|
Market Cap | $1.04T | $21.63B |
Volume | 3,064,878 | 2,324,729 |
Sector | Health | Consumer Cyclical |
52-Week High | $1.28K | $142.56 |
52-Week Low | $799.57 | $110.11 |
Typical Hold Time | 93 Days | 91 Days |
Enterprise Value | $1.09T | $22.04B |
Dividend Yield | 0.59% | 0.92% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,179.27, down 0.79% on the day, with a bullish technical outlook and strong fundamental momentum. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $8.38 surpassing the $6.40 expectation. Revenue surged to $65.18 billion in 2025, driving a net income margin of 33.53%. Recent news highlights promising pipeline developments in weight-loss and diabetes drugs, reinforcing its market leadership.
The outlook remains positive given robust revenue growth, high profitability, and analyst consensus favoring buys. Key risks include competitive pressures in the obesity drug market and execution challenges in scaling production. With a consensus price target of $1,350, representing ~14% upside, the stock offers growth potential but requires monitoring of pipeline progress and market dynamics.
PulteGroup (PHM) trades at $112.12, down 0.19% with a bearish technical outlook. The stock shows mixed fundamentals with recent earnings misses but maintains solid profitability margins. Analyst consensus remains positive with a $139.80 price target, though technical indicators signal selling pressure amid rising mortgage rate concerns affecting the housing sector.
PHM presents value opportunity with attractive P/E of 11.6 and strong cash flow generation, but faces headwinds from rising interest rates impacting housing demand. The stock trades near support at $110 with institutional accumulation providing downside cushion, though sector volatility requires careful risk management.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About PulteGroup, Inc.
PulteGroup Inc is one of the largest homebuilders in the United States, operating in 40 markets across 23 states. The company mainly builds single-family detached homes (85% of unit sales) and offers products to entry-level, move-up, and active-adult buyers. PulteGroup offers homebuyers mortgage financing and title agency services through its financial services segment. The company is headquartered in Atlanta.
Read more on PHM →
